Menu
Curie Logo
Donate
  • Home

Clinical trials - page 5

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Saint-Cloud
    IROCAS - PRODIGE 52
    A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting

  • Paris
    LCB-1801-001
    A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF NI-1801, A BISPECIFIC MESOTHELIN x CD47 ENGAGING ANTIBODY,IN PATIENTS WITH MESOTHELIN EXPRESSING SOLID CANCERS.

    EMANUELA ROMANO

  • Lung cancer
    Paris
    Lunar- 2
    LUNAR-2: a pivotal, randomized, open-label trial of Tumor Treating Fields (TTFields, 150 kHz) combined with pembrolizumab and platinum-based chemotherapy in the treatment of metastatic non·small cell lung cancer.

    NICOLAS GIRARD

  • Saint-Cloud
    M20-621
    A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in;Combination with R-CHOP Compared to R-CHOP in Subjects with New Diagnosed Diffuse Large B-Cell;Lymphoma (DLBCL).

    CLEMENTINE SARKOZY

  • Saint-Cloud
    MAPAM-01
    Therapeutic Nipple Areola Skin-sparing Mastectomy.

    EUGENIE GUILLOT

  • Saint-Cloud
    MCLA-128-CL01
    A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

  • Saint-Cloud
    MCLA-128-CL02
    Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC

    FRANCOIS-CLEMENT BIDARD

  • Paris
    MCLA-158-CL01
    Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors.

    CHRISTOPHE LE TOURNEAU

  • Paris
    MCLA-158-CL02
    A phase 3, open-label, randomized, controlled study aimed at evaluating the efficacy and safety of petosemtamab compared to the investigator's choice of monotherapy in previously treated patients with metastatic/recurring, incurable head and neck squamous cell carcinoma

    CHRISTOPHE LE TOURNEAU

  • ENT/Head and Neck Cancers
    Paris
    MCLA-158-CL03/LiGeR-HN1
    A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

    CHRISTOPHE LE TOURNEAU

  • Thyroid cancer
    Saint-Cloud
    MIBI-THYR
    Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology.

    CAPUCINE RICHARD

  • Saint-Cloud
    MIRASOL
    MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression.

    DIANA BELLO ROUFAI

  • Saint-Cloud
    MK 2140-010
    A Randomized, Open-label, Multisite, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP versus R-CHOP in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) (waveLINE-010).

    CLEMENTINE SARKOZY

  • Lung cancer
    Paris
    MK-2870-004
    A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy;(Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous;Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations.

    CATHERINE DANIEL

  • Breast cancer
    Paris
    MK-2870-010
    An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent;and in Combination with Pembrolizumab Versus Treatment of PhysicianÀs Choice in;Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

    DELPHINE LOIRAT

  • Saint-Cloud
    MK-4280A-008
    Phase 3 Randomized Clinical Study of MK-4280A (coformulated;favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus PhysicianÀs Choice;Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma;(KEYFORM-008).

    Adrien GILBERT

  • Saint-Cloud
    MK3475 B96 ENGOT ov65
    A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

    DIANA BELLO ROUFAI

  • Saint-Cloud
    MK3475-826 (Keynote-826)
    A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

  • Hématologie / cancers du sang
    Saint-Cloud
    MO44869_GLOASIS
    https://clinicaltrials.gov/study/NCT06558604?term=gloasis&rank=1

    STEVEN LE GOUILL

  • Paris
    MOST Plus
    My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors

    CHRISTOPHE LE TOURNEAU

  • Saint-Cloud
    MS200647-0020/BREAST020
    A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer

    FRANCOIS-CLEMENT BIDARD

  • Childhood and adolescent cancers
    Paris
    MUCILA
    Multicenter double blind randomized placebo-controlled trial assessing the efficacy of low-level laser therapy in the prevention of chemotherapy-induced mucositis in children and young adults treated for a tumoral disease.

    CAMILLE CORDERO

  • Lymphoma
    Saint-Cloud
    MorningLyte
    This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.

    CLEMENTINE SARKOZY

  • Saint-Cloud
    NANORAD2
    Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial.

  • Breast cancer
    Saint-Cloud
    NEOVAB
    Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB)

  • ENT/Head and Neck Cancers
    Paris
    Nanoray-312
    A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC

    MARIA LESNIK

  • Paris
    OCEAN-OT
    the Impact of Occupational Therapy : a Multicenter Randomized Controlled Trial (OCEAN-OT).

    FLORENCE ROLLOT TRAD

  • Saint-Cloud
    PACHA 01
    Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial

  • Paris, Saint-Cloud
    PALLU
    A randomized comparative prospective multicenter study of the efficacy of a systematic referral to palliative care of patients who need for palliative care during an unscheduled visit in comprehensive anticancer centers.

    CAROLE BOULEUC-PARROT

  • Saint-Cloud
    PERSPECTIVE (MS202202-0002)
    A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE)

<
1 ...57
>